Blueroot Health Aller-C Recall: The GMP Lessons Behind Undeclared Allergens in a Vegan Supplement

Undeclared allergen recalls are almost never just a labeling problem. The label is where the failure becomes visible, but the root cause is almost always upstream: a raw material that was not tested on arrival, an allergen hazard that was not identified in the hazard analysis, a supplier whose certificate of analysis was accepted without verification, or a shared-equipment cleaning program that was never validated against the allergens actually running through the facility.

On March 27, 2026, Blueroot Health of Middletown, Connecticut announced a voluntary allergy alert on its Vital Nutrients Aller-C dietary supplement after routine internal testing identified the potential presence of undeclared egg, hazelnut, and soy in vegan capsules bearing no allergen declarations whatsoever. Three of the nine major food allergens. In a product explicitly marketed as vegan. Released to consumers nationwide through VitalNutrients.co and other online retailers.

This recall is a case study in what a functioning allergen control program under 21 CFR Part 111 is specifically designed to prevent. The fact that internal testing caught the problem before any illnesses were reported is the only thing that went right. Everything that allowed the contamination to reach finished product in the first place is the focus of this analysis.

What Happened: The Facts

Blueroot Health issued a voluntary allergy alert on March 27, 2026 for its Vital Nutrients Aller-C dietary supplement, sold in 100-count and 200-count white plastic bottles of vegan capsules. (FDA recall notice)

The affected lot numbers are 25E04-A and 25E04-B, both with an expiration date of 05/27. The affected UPCs are:

200-capsule (Lot 25E04-B): UPC 693465524213 and 693465000090
100-capsule (Lots 25E04-A and 25E04-B): UPC 693465524114 and 693465000083

The product was distributed nationwide through VitalNutrients.co and other online retailers. The contamination was discovered through routine internal testing. As of the recall date, no consumer illnesses or adverse reactions had been reported.

Consumers are directed to stop using the product immediately and contact Blueroot Health for a replacement. The company can be reached at (888) 328-9992, Monday through Friday, 8 AM to 7 PM ET, or by email at [email protected].

The allergens at issue are egg, hazelnut (a tree nut), and soy. All three are major food allergens under federal law. None were declared on the label. The product is marketed as vegan, meaning consumers with egg or dairy allergies would have had additional reason to believe it was safe. It was not.

Why This Matters: Allergen Risk Is Non-Negotiable

Food allergies affect an estimated 33 million Americans. For individuals with IgE-mediated allergies to tree nuts, eggs, or soy, exposure to even small quantities of the allergen can trigger reactions ranging from hives and gastrointestinal distress to anaphylaxis — a life-threatening systemic response that can cause death without rapid treatment.

Undeclared allergens are classified by FDA as Class I recalls — the most serious recall classification, reserved for situations where there is a reasonable probability that the use of or exposure to the product will cause serious adverse health consequences or death. The agency does not treat undeclared allergens as a paperwork violation. It treats them as a public health emergency.

Undeclared allergens have consistently ranked among the leading causes of FDA-initiated food and supplement recalls. The January 2026 recall data alone included eight separate allergen-related events. Every one of those recalls represents a failure point that should have been caught by the manufacturer's quality system before the product reached a consumer.

The Vital Nutrients Aller-C situation adds a layer of complexity beyond a standard undeclared allergen event: the product is labeled vegan. Consumers who rely on vegan labeling do so because they expect the product contains no animal-derived ingredients. Egg violates that expectation directly. The allergen risk and the marketing claim failure compound each other.

The Regulatory Framework: What the Law Requires

FALCPA and the Nine Major Allergens

The Food Allergen Labeling and Consumer Protection Act of 2004 (FALCPA), codified at 21 U.S.C. § 343(w), established the legal requirement to declare major food allergens on the labels of packaged foods, including dietary supplements. The original eight major allergens under FALCPA are: milk, eggs, fish, shellfish, tree nuts (which explicitly includes hazelnut), wheat, peanuts, and soybeans.

FALCPA requires that whenever a major allergen is present in a product — whether as an ingredient, as part of a flavoring, coloring, or incidental additive, or through cross-contact — the common name of the food source must appear either in the ingredient list or in a separate "Contains" statement immediately following or adjacent to the ingredient list.

The FASTER Act of 2021 (Food Allergy Safety, Treatment, Education, and Research Act) expanded the allergen list by adding sesame as the ninth major allergen, effective January 1, 2023. All FALCPA requirements that apply to the original eight allergens now apply equally to sesame. Manufacturers who have not updated their allergen hazard analyses to include sesame since 2023 have an open compliance gap.

For dietary supplement manufacturers: FALCPA applies to dietary supplements. The exemption that allows some highly refined oils to avoid allergen declaration does not apply to the allergens at issue in this recall. Egg, hazelnut, and soy present in a dietary supplement must be declared, period.

21 CFR Part 111: The Supplement GMP Standard

Dietary supplement manufacturers are governed by 21 CFR Part 111 — Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. This is the primary GMP regulation for supplements, and it is where allergen controls for this industry category live.

Two sections are directly relevant to any allergen recall event:

21 CFR 111.70 requires that manufacturers establish specifications for each component used in a dietary supplement, including raw materials, in-process materials, and finished products. Those specifications must be sufficient to ensure the product meets its identity, purity, strength, and composition requirements. For a vegan product with no allergen declarations, the specifications must be capable of ruling out the presence of egg, hazelnut, and soy at every stage of production.

21 CFR 111.75 requires that manufacturers actually test or examine components against those specifications before use — not simply accept a supplier's documentation at face value. At minimum, a manufacturer must conduct identity testing on every incoming lot of dietary ingredients. For other components, including raw materials that could introduce allergens, the manufacturer must confirm that applicable specifications are met. The standard does not allow passive reliance on a certificate of analysis as a substitute for verification.

FSMA Preventive Controls: The Allergen Hazard Analysis Framework

While 21 CFR Part 117 (FSMA Preventive Controls for Human Food) provides a general exemption for dietary supplement facilities that are operating in compliance with Part 111, the preventive controls framework it establishes is the industry standard for thinking about allergen hazards systematically. Many supplement manufacturers voluntarily operate their allergen programs against the Part 117 model because it is more structured and defensible than relying on Part 111's specifications-and-testing framework alone.

Under that model, undeclared allergens are identified as hazards requiring preventive controls — not just reactive testing. The controls must address the hazard at the point in the process where it is most likely to occur: incoming raw material receipt, shared equipment use, labeling reconciliation, and finished product release. Monitoring, corrective action, and verification records are required for each control.

Whether a dietary supplement manufacturer operates formally under Part 111 or voluntarily applies the Part 117 allergen control model, the practical requirements are the same: identify the allergen hazards, implement controls that actually prevent them, verify that the controls are working, and maintain records that demonstrate it.

What Likely Went Wrong: Root Cause Analysis

Without access to Blueroot Health's investigation records, it is not possible to state definitively how egg, hazelnut, and soy entered a product that should have contained none of them. But the industry patterns behind this type of event are well established, and they are worth examining as learning points for any supplement manufacturer conducting its own allergen program review.

Supplier-Introduced Allergens

The most common pathway for undeclared allergens in dietary supplements is the raw material supply chain. A supplier changes a manufacturing process, begins sourcing an ingredient from a new facility, or switches a carrier or excipient — and none of those changes are disclosed in the updated certificate of analysis. The manufacturer receives a document that says the component is allergen-free, accepts it without testing, and incorporates the material into production.

This is precisely why 21 CFR 111.75 requires manufacturers to verify specifications rather than simply collect paperwork. A certificate of analysis is a representation made by the supplier about a specific lot. It is not a substitute for independent verification. Any incoming raw material that could potentially carry egg, hazelnut, or soy — including plant-based excipients, encapsulation materials, processing aids, and flow agents — should be tested for those allergens before being released for use in a product that bears no allergen declarations.

Shared Equipment and Cross-Contact

If the facility that manufactured Vital Nutrients Aller-C also processes products containing egg, hazelnut, or soy, shared equipment is a possible contamination pathway. Encapsulation lines, blending equipment, and conveying systems that are not rigorously cleaned between allergen-containing and allergen-free production runs can transfer residual allergen protein to subsequent batches.

Cleaning validation in a shared-equipment environment requires more than a standard cleaning procedure. It requires a demonstrated protocol that specifically targets the allergens at issue, verified by allergen-specific testing of equipment swabs after cleaning and before the next production run begins. If that validation has not been performed, the cleaning procedure — however thorough it appears on paper — cannot be relied upon to prevent cross-contact.

Inadequate Allergen Hazard Analysis

The most fundamental failure mode is one that precedes all of the above: a hazard analysis that did not identify egg, hazelnut, or soy as potential allergen hazards for this product in this facility. If the hazard analysis said there were no allergen risks, there would have been no controls implemented to prevent them. No incoming testing. No cleaning validation. No label verification step requiring confirmation that the finished product matched the allergen declarations on the label.

A hazard analysis that misses a hazard does not protect the consumer — it protects the status quo until something goes wrong. The fact that internal testing eventually caught the contamination suggests a testing program was in place. The question is why the hazard was not identified and controlled before it reached the testing stage.

The "Vegan" Label Problem: A Compounded Failure

Egg is an animal product. A vegan product by any standard definition contains no eggs. When a product labeled as vegan contains egg — and the egg is undeclared — the failure is not simply a FALCPA violation. It is also a marketing claim that is objectively false.

FDA has authority over the truthfulness and non-misleading nature of dietary supplement labeling under sections 403 and 201(n) of the Federal Food, Drug, and Cosmetic Act. A vegan claim that is not substantiated by the product's actual composition is a misbranding violation independent of and in addition to the FALCPA violation for failing to declare the egg allergen.

The Federal Trade Commission (FTC) also has jurisdiction over advertising claims made for dietary supplements sold to consumers. A vegan claim that appears in online product listings, marketing copy, or social media — and that is contradicted by the product's actual formulation — creates FTC exposure in addition to FDA exposure. For a product distributed nationwide through an online storefront, that advertising dimension is significant.

From a consumer trust standpoint, the vegan label problem goes beyond regulatory exposure. Consumers who purchase a vegan supplement are making a decision based on a specific expectation: that the product contains no animal products. That expectation shapes their purchasing behavior in ways that no allergen consumer advisory can fully undo. The damage to product trust compounds the regulatory consequence.

Manufacturers making vegan claims must be able to verify, through raw material testing, supplier audits, and finished product testing, that no animal-derived ingredients are present. That verification is not optional as a matter of either law or consumer trust.

Practical Compliance Guidance for Dietary Supplement Manufacturers

The Vital Nutrients Aller-C recall provides a clear template for what an allergen control program under 21 CFR Part 111 needs to address. Here is where to focus.

Allergen Hazard Analysis Under 21 CFR Part 111

Start with a documented allergen hazard analysis for every product you manufacture. The analysis should address:

Which of the nine major allergens (milk, eggs, fish, shellfish, tree nuts, wheat, peanuts, soybeans, sesame) are present in any raw material, excipient, processing aid, encapsulation material, or coating used in the product
Whether any allergens are handled elsewhere in the facility in products that share equipment, airspace, or personnel with this product
Whether the product's label accurately declares all allergens that could be present based on ingredients and cross-contact potential
Whether any marketing claims (including vegan, dairy-free, nut-free) require additional verification steps

The hazard analysis is not a one-time document. It requires re-evaluation whenever a raw material source changes, a new product is introduced to the facility, or equipment is modified or shared in a new configuration.

Supplier Qualification and Certificate of Analysis Review

Supplier qualification for allergen purposes goes beyond collecting a questionnaire and a certificate of analysis. An effective program includes:

An allergen-specific supplier questionnaire that asks about manufacturing site allergens, shared equipment, change notification policies, and testing protocols
A requirement that suppliers notify you of any changes to their manufacturing process, sourcing, or facility that could affect allergen status
Periodic supplier audits or third-party audit reports that include verification of allergen controls
Review of certificates of analysis specifically for allergen statements, with attention to the testing method used (ELISA, PCR, etc.) and the detection limits relative to your product specifications

A certificate of analysis that simply states "allergen-free" without specifying the testing method or detection limit provides limited assurance. Know what your suppliers are actually testing for and how.

Incoming Raw Material Testing Protocols

Under 21 CFR 111.75, you must verify that component specifications are met before materials are used in production. For a product bearing no allergen declarations, that means incoming testing for the allergens that could plausibly be present based on your hazard analysis. The testing program should specify:

Which raw materials require allergen testing on each incoming lot
Which allergens are tested for each material, based on the hazard analysis
The analytical method used (ELISA lateral flow, quantitative ELISA, PCR) and the sensitivity required
The action level at which a lot is rejected
The quarantine and disposition process for lots that fail testing

Relying solely on your supplier's testing does not satisfy the requirement to verify specifications. At minimum, periodic independent testing of incoming lots — even when certificates of analysis are provided — is good practice. For high-risk materials or products with strict marketing claims like vegan labeling, independent lot testing should be routine.

Allergen Segregation and Cleaning Validation

If your facility handles products containing major allergens on shared equipment, you need a cleaning validation program that is specific to allergens, not just a general sanitation program. That program should include:

Identification of all allergens present in the facility and all products that contain them
A production scheduling system that minimizes allergen-to-non-allergen changeovers, or that sequences allergen-containing runs at the end of a campaign before a full validated clean
A written cleaning procedure for allergen changeovers, specifying cleaning agents, contact times, rinse requirements, and the sequence of steps
Validation data demonstrating that the cleaning procedure reduces allergen residue on food-contact surfaces to below the action level established in your specifications — using allergen-specific swab testing (not just visual inspection or ATP swabs)
Routine monitoring of cleaning effectiveness between production runs, with records

Physical segregation is always preferable to relying on cleaning when the stakes are high. Dedicated equipment for allergen-free products eliminates the cross-contact risk entirely. Where dedicated equipment is not feasible, validated cleaning is the minimum requirement.

Label Review SOPs and Final Label Reconciliation

Every label that goes on a dietary supplement product must be reviewed against the formulation before it is approved for use. That review should confirm:

That all ingredients in the formulation are accurately declared on the label
That all major allergens present in the formulation are declared either in the ingredient list or in a "Contains" statement
That marketing claims on the label (vegan, allergen-free, dairy-free, etc.) are consistent with the formulation and with the allergen testing results for the product
That the label has not been changed since the last review in any way that affects the allergen declarations

Label approval should be a quality function, not a marketing function. The person approving a label for production use should be confirming regulatory compliance, not aesthetics. Any label change — including an artwork refresh that does not touch the ingredient panel — should trigger a full allergen declaration review before the updated label is put into production.

Finished Product Allergen Testing Before Release

For products bearing no allergen declarations, especially those making positive claims like vegan or allergen-free, finished product allergen testing before lot release provides an additional verification layer that incoming material testing and process controls alone cannot replicate. Finished product testing catches what every upstream control missed — and in the Blueroot Health case, it is what eventually identified the problem.

The testing program for finished products should specify:

Which allergens are tested in each product based on the hazard analysis
The sampling plan for each lot (number of units, sampling locations in the batch)
The analytical method and detection limits
The release criteria and the hold/reject process for lots that fail

Finished product testing should be viewed as a quality verification step, not as your primary allergen control. If finished product testing is the only thing standing between an allergen-contaminated lot and a consumer, your upstream controls are insufficient.

Shared Facility and "May Contain" Statements

When allergen cross-contact cannot be fully eliminated through cleaning and physical controls, manufacturers have the option of including advisory statements on the label — commonly formatted as "Manufactured in a facility that also processes [allergen]" or "May contain [allergen]." These statements are voluntary, not required by FALCPA, but they serve a consumer protection function when cross-contact risk exists but cannot be quantified or fully controlled.

Advisory statements are not a substitute for allergen controls. They do not excuse the failure to implement appropriate cleaning and segregation procedures. And they must be accurate — if your facility processes hazelnut on shared equipment with products that are not supposed to contain hazelnut, and you have not validated that your cleaning process removes hazelnut residue to safe levels, an advisory statement is appropriate. Omitting the advisory statement in that scenario is itself a consumer safety failure.

When You Find a Problem: What to Do

Blueroot Health discovered the contamination through routine internal testing and acted promptly — issuing a voluntary allergy alert and establishing a consumer replacement program. That response reflects the correct sequence when an undeclared allergen problem is identified in finished product.

When your testing reveals a potential undeclared allergen issue, the immediate steps are:

Quarantine the affected lots — stop any further distribution immediately while the investigation is conducted
Notify your quality leadership and begin a documented root cause investigation
Assess the health risk — determine whether the allergen present and the population at risk create a reasonable probability of serious adverse health consequences. If yes, this is a Class I scenario
Make the recall decision — voluntary recalls initiated by the manufacturer are the most common response. FDA can also request a recall or, in extreme cases, mandate one under FSMA authority
Notify FDA — under 21 CFR Part 7, a firm conducting a recall must submit an initial recall notification report to the appropriate FDA district office. The report covers the product, the problem, the affected distribution, and the corrective action plan
Notify your distribution chain — notify all customers and distributors who received the affected lots and provide instructions for returning or destroying the product
Notify consumers — issue a public-facing consumer advisory through your website and, as appropriate, through FDA's recall database

FDA classifies recalls on a three-tier system. Class I is for products that present a reasonable probability of serious adverse health consequences or death — where undeclared major allergens almost always land. Class II is for products that may cause temporary or reversible adverse health consequences. Class III is for products unlikely to cause adverse health consequences.

A well-functioning quality system includes a mock recall program: a periodic exercise in which the quality team drills the recall process end-to-end — tracing a lot from raw material receipt through distribution, identifying all affected product, and completing a paper recall within the timeframes your SOP specifies. Mock recalls expose gaps in traceability, record retention, and response procedures before a real event forces the issue.

Key Deadlines and Action Items for Manufacturers

The Blueroot Health recall is a prompt to audit your own allergen program against the requirements of 21 CFR Part 111 and the expectations FDA brings to supplement facility inspections. Here is a prioritized checklist:

Review your allergen hazard analysis for every product you manufacture. Confirm it addresses all nine major allergens, including sesame (effective since January 1, 2023 under the FASTER Act). Update any analysis that predates your last raw material source change.
Pull your incoming testing records for the last 12 months of raw material receipts. Confirm that allergen testing was performed on materials that could introduce egg, tree nuts, or soy into products where those allergens are not declared.
Review every certificate of analysis you received from raw material suppliers in the last 12 months. For each allergen-relevant material, confirm that the CoA specifies the testing method and detection limit, not just a pass/fail conclusion.
Walk your cleaning validation records for any shared equipment used on both allergen-containing and allergen-free products. Confirm that validation data exists and that it uses allergen-specific surface swab testing, not visual inspection alone.
Audit your current finished product labels against the current formulations. Confirm that all major allergens in the formulation are declared and that any marketing claims (vegan, allergen-free, etc.) are substantiated by testing.
Confirm your mock recall program is current. If your last mock recall exercise was more than 12 months ago, schedule one. Your SOP should require annual mock recall drills at minimum.
Review your supplier quality agreements. Confirm that all suppliers of raw materials used in products bearing no allergen declarations are contractually required to notify you of changes to their manufacturing process, sourcing, or facility allergen status.
Verify your FDA notification procedures. Confirm that your quality team knows the 21 CFR Part 7 recall reporting requirements and has a documented escalation path from problem identification to FDA notification.

Recalls Like This Are Preventable

The Blueroot Health voluntary allergy alert on Vital Nutrients Aller-C shows what happens when allergen controls break down in the dietary supplement supply chain. Three undeclared allergens in a product that was labeled vegan, marketed nationally, and distributed broadly is not a minor quality event. It is a system failure — one that a properly implemented allergen program under 21 CFR Part 111 is designed to prevent.

The good news is that Blueroot Health's internal testing caught the problem before any consumer reported an illness. The better outcome would have been a quality system that prevented the contamination from reaching finished product in the first place. The difference between those two outcomes is an allergen hazard analysis that identifies the risk, incoming testing that catches contaminated materials before they enter production, cleaning validation that prevents cross-contact, and label review that confirms what the consumer is told about what they are taking.

If your allergen program cannot confidently answer the question "How do we know egg, hazelnut, and soy are not in this product?" for every lot you release, that is your most urgent compliance gap — not the label.

If you need help building or auditing an allergen control program for your dietary supplement facility, assessing compliance with 21 CFR Part 111, or preparing for an FDA inspection, Certify Consulting works with supplement manufacturers across exactly these challenges. The goal is a quality system that protects your consumers and your brand before a recall forces the issue.

Last updated: April 9, 2026. FDA recall source: FDA Safety Alerts — Blueroot Health Vital Nutrients Aller-C.

Blueroot Health Issues Voluntary Allergy Alert on Undeclared Egg, Hazelnut, and Soy in Vital Nutrients Aller-C: The GMP Lessons Every Supplement Manufacturer Needs to Hear